SQZ Biotechnologies Company (SQZ)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions.
Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents.
Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
|IPO Date||Oct 30, 2020|
200 Arsenal Yards Boulevard
Watertown, MA 02472
|Phone||617 758 8672|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Armon R. Sharei Ph.D.||Co-Founder, President, Chief Executive Officer, Interim Principal Financial Officer and Director|
|Lawrence J. Knopf||General Counsel and Secretary|
|Teri Loxam||Consultant and Advisor|
|Micah Zajic||Chief Business Officer|
|Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD||Co-Founder and Member of Scientific Advisory Board|
|Richard Capasso||Chief Accounting Officer|
|Dr. Howard Bernstein||Chief Scientific Officer|
|David First||Chief People Officer|
Latest SEC Filings
|Nov 19, 2021||EFFECT||Notice of Effectiveness|
|Nov 18, 2021||8-K/A||Current report|
|Nov 16, 2021||3||Initial statement of beneficial ownership of securities|
|Nov 10, 2021||S-3||Registration statement under Securities Act of 1933|
|Nov 10, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 4, 2021||8-K||Current report|
|Oct 26, 2021||8-K||Current report|
|Sep 13, 2021||8-K||Current report|
|Sep 2, 2021||8-K||Current report|
|Aug 9, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|View All SEC Filings|